Amisulpride is a neuroleptic. Amisulpride binds selectively with a high affinity to human dopaminergic D2/D3 receptor subtypes whereas it is devoid of affinity for D1, D4 and D5 receptor subtypes.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Amisulpride is the active ingredient of these drugs:
Cyprus Lithuania Netherlands
Australia Tunisia
Poland
Estonia Lithuania Poland
Poland
Spain
United States
Italy
Brazil
Tunisia
Australia Austria Cyprus Estonia France
Cyprus
Australia New Zealand
Poland
Tunisia
Tunisia
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):